Best Practices for Operationalizing Bispecific Antibody Therapy in Follicular Lymphoma

Successfully implementing bispecific antibody therapy for follicular lymphoma requires robust operational protocols and seamless care transitions. Best practices include developing standardized workflows for administration, monitoring, and toxicity management that are tailored to each health system’s resources. Key stakeholders—physicians, advanced practice providers, nurses, pharmacists, and administrative staff—play distinct but complementary roles, from patient selection and dosing to education and coordination of follow-up. Optimizing transitions of care between inpatient and outpatient settings is critical, particularly for managing adverse events like cytokine release syndrome or infusion reactions, ensuring continuity, and reducing readmissions. Operational hurdles such as staff training, scheduling complexity, and resource allocation must be proactively addressed through multidisciplinary collaboration and iterative process improvement. By integrating these strategies, health systems can safely expand the use of bispecific antibodies while enhancing efficiency, patient experience, and overall treatment outcomes.